Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04626 (
erbB-2
)
5,251
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
HER-2/neu
oncogene, a member of the epidermal growth factor receptor or erb gene family, encodes a transmembrane tyrosine kinase receptor that has been linked to prognosis and response to therapy with the anti-HER-2-humanized monoclonal antibody, trastuzumab (Herceptin, Genentech, South
San
Francisco, CA) in patients with advanced metastatic breast cancer.
HER-2/neu
status has also been tested for its ability to predict the response of breast cancer to other therapies including hormonal therapies, topoisomerase inhibitors, and anthracyclines. This review includes an analysis of 80 published studies encompassing more than 25,000 patients designed to consider the relative advantages and disadvantages of the various methods of measuring
HER-2/neu
in clinical breast cancer specimens. Southern blotting, PCR amplification detection, and fluorescence in situ hybridization assays designed to detect
HER-2/neu
gene amplification are compared with
HER-2/neu
protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of
HER-2/neu
overexpression in ductal carcinoma in situ and the
HER-2/neu
status in uncommon female breast conditions and male breast cancer are also considered. The role of
HER-2/neu
testing for the prediction of response to trastuzumab therapy in breast cancer is reviewed along with the current studies designed to test whether
HER-2/neu
status can predict the response to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review will also evaluate the status of serum-based testing for circulating
HER-2/neu
receptor protein and its ability to predict disease outcome and therapy response.
...
PMID:Targeted therapy in breast cancer: the HER-2/neu gene and protein. 1476 15
<< Previous
1
2